18
Registered trials
13
Recruiting
3
Completed trials
1
Countries active
23
Unique IMPs
100%
Results reported
100%
3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).
Top indications
Top IMPs
EPLERENONE
2
SULFUR HEXAFLUORIDE
2
(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
1
ALTEPLASE
1
CSM-GW
1
EMPAGLIFLOZIN
1
EPINEPHRINE BITARTRATE
1
EVEROLIMUS
1
HUMAN ALBUMIN SOLUTION
1
IOHEXOL
1
LEVOSIMENDAN
1
LUTETIUM (177LU) OXODOTREOTIDE
1
All trials
18 totalShowing 1–18 of 18 trials